ALK and non-small cell lung carcinoma: Nivolumab, an anti-PD-1 antibody, is currently used for second-line treatment in Anaplastic Lymphoma Kinase (ALK) and Epidermal Growth Factor Receptor (EGFR) wild-type advanced NSCLC [2,3].